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A B S T R A C T
Findings from numerous studies suggest an association between low cholesterol levels and suicidal behavior in pa-
tients with different psychiatric diagnoses. The aims of this case-control study were to test whether cholesterol levels in
male suicidal patients (N=20) with borderline personality disorder (BPD) are lower than in male non-suicidal patients
(N=20) with BPD and male healthy control group (N=20), and to evaluate the influence of structured individual psy-
choanalytic psychotherapy on suicidal behavior. The groups were matched for age and body mass index (BMI). Results
showed that serum cholesterol levels did not differ significantly between suicidal and non-suicidal BPD patients and
healthy controls. The level of psychopathology (measured by Brief Psychiatric Rating Scale and Hamilton Depression
Rating Scale) was significantly higher in the group of suicidal patients, which indicates the importance of evaluating
particular clinical symptoms in BPD, in order to prevent suicidal behavior. Non-suicidal male patients suffering from
BPD received more frequently structured individual psychoanalytic psychotherapy prior to the hospitalization than sui-
cidal group. These results emphasized the role of this type of psychotherapy in preventing suicidal behavior in BPD pa-
tients.
Key words: cholesterol, suicidality, borderline personality disorder, men, psychoanalytic psychotherapy
Introduction
Borderline personality disorder (BPD) is one of the
most widely researched mental disorders and by far the
most extensively researched personality disorder. The
BPD consists of a cluster of symptoms characterized by
unstable, impulsive behavior – fear of abandonment, un-
stable interpersonal relationships, identity disturbance,
impulsiveness, self-mutilation and/or suicide, affective
instability, empty feelings, inappropriate anger, and dis-
sociation (DSM-IV-TR – Diagnostics and Statistics Man-
ual IV-Text Revised)1. Millon2 has suggested that the ap-
pearance of BPD creates psychosocial epidemics. This
contrasts the fact that empirically based treatment re-
search on suicidality of patients with BPD is sparse. The
psychotherapeutic treatment of suicidal patients with
BPD is one of the biggest challenges facing mental health
professionals3–4. Suicidality in BPD peaks when patients
are in their early 20s, but completed suicide is most com-
mon after 30 years of age and usually occurs in patients
who fail to recover after many attempts or treatment5.
The neurobiology of suicide in patients with BPD is
still unclear. Among the biological hypotheses of suici-
dality, low blood cholesterol levels have been extensively
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explored. The relationship between serum cholesterol
and suicidality does not seem to be limited to individuals
with a certain psychiatric disorder. Our previous studies
confirmed the role of cholesterol in suicidal behavior,
showing lower cholesterol levels in suicidal patients with
different forms of psychotic disorders6–10 and bipolar af-
fective disorder11, which are frequent comorbidities in
patients with BPD12.
Only few papers in the literature evaluated neurobio-
logy of suicidal behavior in BPD. The hypothesis of the
present study was that serum cholesterol levels are lower
in suicidal than in non-suicidal patients with BPD and in
healthy controls. The aim of this case-control study was
to compare serum cholesterol levels in male suicidal pa-
tients (N=20) with BPD with the values in male non-sui-
cidal patients (N=20) with BPD and in male healthy con-
trol group (N=20) and to evaluate the influence of a
prior structured individual psychoanalytic psychother-
apy on suicidal behavior in these patients. The groups
were matched for age and body mass index (BMI).
Materials and Subjects
Participants were male patients, admitted to the De-
partment of Psychiatry, University Hospital Zagreb, dur-
ing the previous period of 12 months. The diagnosis of
BPD was made according to diagnostic criteria of the In-
ternational Statistical Classification of Diseases and Re-
lated Health Problems after structured diagnostic psy-
chiatric interview for ICD-10 (WHO, 1996)13. The socio-
-demographic data are given in Table 1.
Inclusion and exclusion criteria
All patients were free of all medications in the previ-
ous 3 weeks. Within patients, 20 patients were consecu-
tively admitted suicidal men with diagnosis of BPD, and
20 patients were consecutively admitted men with BPD
without suicidal behavior. Healthy male subjects (N=20)
with no history of psychiatric illness and suicidal behav-
ior were randomly selected as a control group. All sub-
jects were closely matched for age. All subjects gave writ-
ten informed consent to participate in the study. This
study was approved by the Clinical Hospital Center Med-
ical Ethics Committee. None of the patients or control
subjects included in the study had used any choles-
terol-lowering drugs before the sampling. The exclusion
criteria were: hypertension, hypothyroidism, diabetes me-
llitus, disorders of the lipoprotein metabolism, including
alcoholism and eating disorders.
Biochemical determination
Blood samples were collected from all subjects at 8.00
a.m. after an overnight fasting, and serum concentration
of cholesterol was determined enzymatically, immedi-
ately after the blood collection. The assays were done us-
ing commercial kits (Olympus Diagnostic GmbH, Ham-
burg, Germany) on Olympus AU 600 automatic analyzer.
Body mass index (BMI) was used as a marker of the di-
etary habits.
Clinical evaluations
The trained psychiatrists performed clinical evalua-
tion. The Brief Psychiatric Rating Scale – BPRS14 was
administered to assess a broad range of psychopathology.
Patients were classified as suicidal at the hospital admis-
sion if a suicidal ideation, or a suicide attempt, or both,
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TABLE 1




















c2 =0.616; df =2; p= 0.735
Marital status
Married 6 6 9




Widower 0 1 0











c2 =4.667; df= 4; p= 0.323
Employment
Employed 2 6 10
Unemployed 8 8 5
Retired 4 2 1
Student 6 4 4
c2 =8.762; df= 6; p= 0.187


















c2 =4.970; df= 4; p= 0.290
were present. Suicidality was defined if patients had 2 or
more scores on the BPRS, on the item 4 (item on suicide).
Non-suicidal patients had score 1 on the BPRS item 4.
Hamilton Depression Rating Scale15, HDRS-17 (Hamil-
ton, 1960) was applied to assess depressive symptoms.
Structured individual psychoanalytic psychotherapy prior
to the hospitalization (during the previous 6 months)
was detected in every patient, as well as the family his-
tory of suicidal behavior.
Statistical analysis
The results were expressed as X±SD. All data were
evaluated using one-way analysis of variance (ANOVA)
followed by a Scheffee’s multiple comparison test. When
two groups were compared, Student’s t-test was used.
Because age and BMI might influence cholesterol levels,
these variables were included as covariates within analy-
sis of covariance (ANCOVA) in the comparison of serum
cholesterol levels. The differences in the socio-demo-
graphic variables between suicidal and non-suicidal groups
were assessed using a Chi square (c2) test. A significance
was accepted when p<0.05. Statistical analyses were per-
formed with the statistical package SPSS version 10 for
Windows.
Results
The socio-demographic characteristics of the subjects
are shown in Table 1. There were no significant (c2 test)
differences in the occurrence of the socio-demographic
variables: in the family status, marital status, degree of
education, employment and family history of suicidal be-
havior between suicidal and non-suicidal patients (Table
1). Suicidal patients, compared to non-suicidal patients,
reported more cases of family history of suicidal behav-
ior, but these differences were not significant (Table 1).
Age of the patients and BMI did not differ significantly
(ANOVA) between suicidal and non-suicidal patients and
healthy control groups (Table 2). Serum cholesterol lev-
els were not significantly different (ANOVA) between
suicidal and non-suicidal (p=0.155, Scheffe’s test) pati-
ents, or suicidal compared to healthy (p=0.100, Scheffe’s
test) subjects (Table 2). Serum cholesterol values were
slightly reduced (by 8%) in suicidal patients, but these
differences were not significant. These results remained
the same after controlling for age and BMI (ANCOVA).
The HDRS-17 scores were significantly (Student’s
t-test) higher in suicidal compared to non-suicidal pa-
tients (Table 3). The BPRS scores were also significantly
(Student’s t-test) higher in suicidal compared to non-sui-
cidal patients (Table 3). Seven out of 24 symptoms on
BPRS were significantly higher in suicidal patients, com-
pared to non-suicidal patients – anxiety, depression, sui-
cidality, grandiosity, tension, excitement and motor hy-
peractivity (Table 3). There was no significant correlation
between cholesterol and each symptom of the BPRS.
There was a significant (c2-test) difference in the fre-
quency of the structured individual psychoanalytic psy-
chotherapy received prior to the hospitalization between
suicidal and non-suicidal patients with BPD. Non-sui-
cidal male patients with BPD received more frequently
(c2-test) structured individual psychoanalytic psycho-
therapy prior to the hospitalization than suicidal group
(Table 4).
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TABLE 2
AGE, BMI AND CHOLESTEROL (X±SD) IN MALE SUICIDAL AND NON-SUICIDAL PATIENTS SUFFERING FROM BORDERLINE
PERSONALITY DISORDER AND IN HEALTHY CONTROL SUBJECTS
Suicidal BPD group (N=20) Non-suicidal BPD group (N=20) Control group (N=20) F p
Age 29.00±6.54 29.85±7.57 32.10±7.23 1.009 0.371
BMI 24.64±1.79 25.32±2.36 25.20±2.13 0.595 0.555
Cholesterol mmol/L 4.88±0.96 5.28±0.96 5.32±0.85 1.560 0.219
TABLE 3
HDRS-17 AND BPRS (X±SD) IN MALE SUICIDAL AND NON-SUICIDAL PATIENTS SUFFERING FROM BORDERLINE PERSONALITY
DISORDER
Scale Suicidal BPD group Non-suicidal BPD group Student t-test p
HDRS-17 30.15±9.09 16.55±10.55 4.367 0.000
BPRS 72.10±8.09 55.40±9.06 6.145 0.000
Items on BPRS, significantly differ between groups – 7 items:
Anxiety 4.95±1.05 3.00±0.91 6.253 0.000
Depression 5.10±0.71 2.65±0.67 11.149 0.000
Suicidality 4.75±0.44 1.00±0.00 37.749 0.000
Grandiosity 4.85±0.81 2.40±0.50 11.466 0.000
Tension 4.20±0.76 2.00±0.56 10.341 0.000
Excitement 3.15±1.26 2.35±1.13 2.101 0.042
Motor hyperactivity 3.10±1.33 2.30±0.97 2.163 0.038
Discussion and Conclusion
Among the biological hypotheses of suicidality, low
blood cholesterol level has been extensively explored.
Numerous studies have shown an association between
low cholesterol levels and suicidal behavior. On the other
hand, this association has been questioned; and some
studies have found a relation between high cholesterol
levels and increased suicidal risk16, while others found no
association between cholesterol and suicidal behavior17.
In order to evaluate the underlying neurobiology of sui-
cidal behavior in borderline patients, we hypothesized
that male suicidal patients suffering from BPD will have
lower serum cholesterol than non-suicidal patients. Re-
sults of this study did not confirm this hypothesis and
our previous results showing reduced cholesterol levels
in suicidal psychiatric patients. This study shows a lack
of significant differences in total serum cholesterol levels
between suicidal borderline patients compared to non-
-suicidal patients with BPD and healthy control subjects.
The discrepancies among studies are in accordance with
the theory that biologic basis of BPD as well as pharma-
cologic treatment of BPD remains incompletely studied
compared to other psychiatric disorders. The core of the
treatment for BPD is still psychotherapy. According to
World Federation of Societies of Biological Psychiatry
(WFSBP) Guidelines for Biological Treatment of Person-
ality Disorders18, no class of pharmacological agents im-
proves BPD psychopathology in general, although the
majority of studies have incorporated measurements of
global functioning in addition to targeting special aspects
of psychopathology. In addition, there is no conclusive ev-
idence that antidepressants reduce impulsive, aggressive
or self-harming behaviors in BPD. According to the hi-
ghly cited Engelberg’s hypothesis19, low serum choles-
terol levels may be associated with reduced lipid micro-
-viscosity in the brain-cell-membrane and may decrease
the exposure of various serotonergic receptors on the
membrane surface, resulting in decreased serotonergic
receptor function and inhibited serotonergic neurotrans-
mission, which may lead to a poorer suppression of im-
pulsive or suicidal behavior. Our results show that chole-
sterol might not be used to distinguish between suicidal
from non-suicidal BPD: this finding might be associated
with the mentioned biologic theory of a poorer response
of BPD patients to antidepressants acting via serotoner-
gic system compared to the patients with the other diag-
nostic categories20.
The HDRS-17 and BPRS scores were significantly
higher in suicidal compared to non-suicidal patients and
this finding could suggest that suicidal behavior is associ-
ated with the higher levels of psychopathology. Seven out
of 24 symptoms on BPRS were significantly higher in
suicidal patients, compared to non-suicidal patients. The-
se non-psychotic symptoms included anxiety, depression,
suicidality, grandiosity, tension, excitement and motor
hyperactivity. On the other hand, psychotic symptoms in
BPRS did not differ significantly between suicidal and
non-suicidal BPD patients. These results suggest that
anxiety, depression, grandiosity, tension, excitement and
motor hyperactivity are associated with development of
suicidal behavior. The other hypothesis of the study was
that structured individual psychoanalytic psychotherapy
during the course of BPD and prior to development of
suicidal behavior might reduce suicidal behavior in BPD
patients. Our results have confirmed that structured in-
dividual psychoanalytic psychotherapy prior to the hos-
pitalization significantly decreased suicidal behavior, sin-
ce non-suicidal male patients suffering from BPD, who
received more frequently this psychotherapy, did not
show suicidal behavior. This finding suggested that al-
though patients with BPD were matched for age, BMI,
socio-demographic characteristics and serum cholesterol
levels, the use of structured individual psychoanalytic
psychotherapy prior to the hospitalization elicited a basic
distinction between suicidal and non-suicidal groups.
The role of structured individual psychoanalytic psycho-
therapy is to enhance patient’s personality and to help
patient to better cope with BPD symptoms. This therapy
might also help patients to better control symptoms of
anxiety, depression, grandiosity, tension, excitement and
motor hyperactivity, which were presented more severely
in suicidal patients with BPD, and to control suicidal
symptoms, in order to prevent suicidal behavior. Limita-
tions of this study were a relatively small patient sample,
and the lack of information on patients’ nutritive habits,
which we plan to perform in one of our further investiga-
tions that will include a larger number of patients. In the
present study there were no data available regarding sev-
eral other factors that may contribute to the alterations
in serum cholesterol levels in suicidal patients, such as
genetic factors and cigarette smoking. A better under-
standing of the neurobiology and psychological factors of
suicidal behavior in BPD patients, and the use of struc-
tured individual psychoanalytic psychotherapy prior to
hospitalization can facilitate the detection of patients
who have a higher risk to attempt suicide, in order to de-
velop better treatment interventions for these patients,
and to prevent suicide.
Acknowledgements
This work was supported byMinistry of Science, Educa-
tion and Sport from the Republic of Croatia, grants No:
108-1080037-0323 and 098-0982522-2455.
D. Mar~inko et al.: Cholesterol in Suicidal Patients with Borderline Personality Disorder, Coll. Antropol. 35 (2011) Suppl. 1: 219–223
222
TABLE 4
STRUCTURED INDIVIDUAL PSYCHOANALYTIC PSYCHOTHERAPY
PRIOR TO THE HOSPITALIZATION FOR MALE SUICIDAL AND







Without psychotherapy 15 3
c2=14.545; df=1; p=0.000
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KONCENTRACIJA KOLESTEROLA I STRUKTURIRANA INDIVIDUALNA PSIHOANALITI^KA
PSIHOTERAPIJA KOD SUICIDALNIH I NESUICIDALNIH MU[KIH BOLESNIKA OBOLJELIH
OD GRANI^NOG POREME]AJA OSOBNOSTI
S A @ E T A K
Rezultati istra`ivanja brojnih studija upu}uju na povezanost niske razine kolesterola i suicidalnog pona{anja kod
bolesnika iz razli~itih dijagnosti~kih kategorija. Cilj ovog istra`ivanja bio je ustanoviti jesu li vrijednosti serumskog
kolesterola kod suicidalnih mu{kih bolesnika s grani~nim poreme}ajem osobnosti (N=20) ni`e u odnosu na nesui-
cidalne mu{ke bolesnike s grani~nim poreme}ajem osobnosti (N=20) i kontrolnu skupinu zdravih mu{kih ispitanika
(N=20) i provjeriti utje~e li strukturirana individualna psihoanaliti~ka psihoterapija na suicidalno pona{anje. Skupine
su bile uskla|ene s obzirom na dob i indeks tjelesne mase (BMI). Rezultati istra`ivanja pokazuju da nema zna~ajnih
razlika u vrijednosti serumskog kolesterola izme|u suicidalnih i nesuicidalnih mu{kih bolesnika s grani~nim poreme-
}ajem osobnosti i kontrolnih zdravih mu{kih ispitanika. Razina psihopatologije (mjerena skalama Brief Psychiatric
Rating Scale i Hamilton Depression Rating Scale) bila je zna~ajno nagla{enija kod suicidalnih bolesnika u odnosu na
nesuicidalne bolesnike, {to upu}uje da je u praksi bitno prepoznati odre|ene klini~ke simptome kod bolesnika s grani-
~nim poreme}ajem osobnosti s ciljem da se prevenira suicidalno pona{anje. Nesuicidalni bolesnici zna~ajno su ~e}e
primili strukturiranu individualnu psihoanaliti~ku psihoterapiju prije hospitalizacije nego suicidalni bolesnici. Ti re-
zultati nagla{avaju ulogu ovog oblika psihoterapije u preveniranju suicidalnog pona{anja u bolesnika sa grani~nim
poreme}ajem osobnosti.
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